• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Evaxion A/S

    10/17/25 8:45:55 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $EVAX alert in real time by email
    6-K 1 f6k_101725.htm FORM 6-K

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     


    FORM 6-K

     

     

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO SECTION 13a-16 OR 15d-16

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of October 2025

     

    Commission File Number: 001-39950

     

     

     

    Evaxion A/S

    (Exact Name of Registrant as Specified in Its Charter)

     

     

     

    Dr. Neergaards Vej 5f

    DK-2970 Hoersholm

    Denmark

    (Address of principal executive offices)

     

     

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

     

    Form 20-F ☒          Form 40-F ☐

     

     

     

    INCORPORATION BY REFERENCE

     

    This report on Form 6-K shall be deemed to be incorporated by reference in Evaxion A/S’s registration statements on Form S-8 (File No. 333-255064), on Form F-3 (File No. 333-265132), on Form F-1, as amended (File No. 333-266050), Form F-1 (File No. 333-276505), Form F-1 (File No. 333-279153), Form F-1 (File No. 333-283304), and Form F-3 (File No. 333- 285778), including any prospectuses forming a part of such registration statements and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished..

     

    Amendment to Articles of Association

     

    On September 25, 2025, the Company sold 1,018,000 American Depositary Shares (the “ADSs”), representing the Company’s ordinary shares, DKK 0.25 nominal value with each ADS representing fifty (50) ordinary shares, at an average price of USD $4.3931 per ADS. The ADSs were sold in an at-the-market (ATM) offering pursuant to the terms and subject to the conditions contained in that certain Capital Demand™ Sales Agreement between the Company and Jones Trading Institutional Services LLC dated October 3, 2022. After deducting fees and expenses, total proceeds to the Company from the sales of the ADSs were approximately $4.3 million. In connection with such sales, the Company registered a share capital increase of nominal DKK 12,725,000 with the Danish Business Authority, with effect date of September 26, 2025, corresponding to an aggregate increase in the Company’s share capital to nominal DKK 91,682,151.50 through the issuance of such 1,018,000 ADSs representing the Company’s ordinary shares.

     

    The Company’s Articles of Association were amended as of September 26, 2025, to reflect these capital increases and are attached hereto as Exhibit 1.1.

     

    The Articles of Association were also amended in connection with the exercise of certain investor warrants. From October 3, 2025 to October 10, 2025, the Company registered aggregate share capital increases of nominal DKK 7,366,312.5 with the Danish Business Authority, corresponding to an aggregate increase in the Company’s share capital to nominal DKK 99,048,464 in connection with the exercise of certain holders of warrants against aggregate cash consideration of DKK 10,344,064.35 (or approximately USD 1,608,519 based on the applicable DKK-USD exchange rate on October 10, 2025), which consisted of payments of both DKK 1,800,162.15 (or approximately USD $279,928 based on the applicable DKK-USD exchange rate on October 10, 2025) and USD 1,343,767.05. Specifically, the Company’s Articles of Association were amended on: (1) October 3, 2025, to reflect the issuance of 21,705,100 ordinary shares corresponding to a share capital increase of nominal DKK 5,426,275 against aggregate cash consideration of USD 1,176,416,42 , (2) October 7, 2025, to reflect the issuance of 1,325,150 ordinary shares corresponding to a share capital increase of nominal DKK 331,287.50 against aggregate cash consideration of USD 71,823.13 , (3), October 8, 2025, to reflect the issuance of 1,625,000 ordinary shares corresponding to a share capital increase of nominal DKK 406,250 against aggregate cash consideration of USD 88,075.00, (4) October 9, 2025 to reflect the issuance of 3,750,000 ordinary shares corresponding to a share capital increase of nominal DKK 937,500 against aggregate cash consideration of DKK 1,446,900 (or approximately USD $ 225,307.15 based on the applicable DKK-USD exchange rate on October 9, 2025), and (5) October 10, 2025 to reflect the issuance of an aggregate of 1,060,000 ordinary shares corresponding to a share capital increase of nominal DKK 265,000 against aggregate cash consideration of both DKK 353,262.15 (or approximately USD $ 54,932.85 based on the applicable DKK-USD exchange rate on October 10, 2025) and USD 7,452.50. The amended Articles of Association are attached hereto as Exhibit 1.1.

     

    Exhibits

     

    Exhibit    
    No.   Description
    1.1   Articles of Association

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

      Evaxion A/S
       
    Date: October 17, 2025 By: /s/ Birgitte Rønø    
        Birgitte Rønø    
       

    Interim Chief Executive Officer

     

     

     

     

    Get the next $EVAX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EVAX

    DatePrice TargetRatingAnalyst
    4/2/2024$8.00Neutral → Buy
    Ladenburg Thalmann
    2/12/2024$14.00Buy
    H.C. Wainwright
    More analyst ratings

    $EVAX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Evaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01

    New biomarker and immune data presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual MeetingFollowing the recent presentation of unprecedented two-year clinical efficacy data from the phase 2 trial, the new data further adds to EVX-01's already strong data package COPENHAGEN, Denmark, November 7, 2025 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces new data exploring immune responses following treatment with AI-designed personalized cancer vaccine EVX-01. The data was presented today in a poster session at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting taking

    11/7/25 5:10:00 PM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Evaxion announces business update and third quarter 2025 financial results

    COPENHAGEN, Denmark, November 6, 2025 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, provides business update and announces third quarter 2025 financial results. Business highlights (since last quarterly update)Evaxion has seen tremendous progress in recent months with several massive achievements. We maintain a high activity level and continue to execute our plans. Highlights include: Evaxion's Board of Directors has appointed Dr Helen Tayton-Martin as new CEO, effective November 24, 2025. Dr Tayton-Martin brings more than 30 years of experience, including biotech M&A, business development and operation

    11/6/25 7:30:00 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Evaxion expands R&D pipeline with new AI-designed precision cancer vaccine candidate

    Evaxion introduces EVX-04, a novel vaccine candidate targeting multiple non-conventional ERV tumor antigens, developed with our AI-Immunology™ platformEVX-04 is a therapeutic cancer vaccine candidate designed for acute myeloid leukemiaNew data showing EVX-04 induces strong T-cell responses and cancer cell killing will be presented at an oral session at the American Society of Hematology (ASH) Annual Meeting and Exposition in Florida on December 6, 2025The concept behind EVX-04 is broadly applicable with potential across cancers where immunotherapies remain inadequate COPENHAGEN, Denmark, November 3, 2025 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company specializing

    11/3/25 9:00:00 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $EVAX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Evaxion Biotech upgraded by Ladenburg Thalmann with a new price target

    Ladenburg Thalmann upgraded Evaxion Biotech from Neutral to Buy and set a new price target of $8.00

    4/2/24 11:31:47 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    H.C. Wainwright initiated coverage on Evaxion Biotech with a new price target

    H.C. Wainwright initiated coverage of Evaxion Biotech with a rating of Buy and set a new price target of $14.00

    2/12/24 6:37:53 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Oppenheimer initiated coverage on Evaxion Biotech A/S with a new price target

    Oppenheimer initiated coverage of Evaxion Biotech A/S with a rating of Outperform and set a new price target of $18.00

    3/8/21 8:22:12 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $EVAX
    SEC Filings

    View All

    SEC Form 6-K filed by Evaxion A/S

    6-K - Evaxion A/S (0001828253) (Filer)

    11/7/25 5:30:11 PM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by Evaxion A/S

    6-K - Evaxion A/S (0001828253) (Filer)

    11/6/25 7:45:07 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by Evaxion A/S

    6-K - Evaxion A/S (0001828253) (Filer)

    11/3/25 9:15:09 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $EVAX
    Leadership Updates

    Live Leadership Updates

    View All

    Evaxion appoints Dr Helen Tayton-Martin as new Chief Executive Officer

    Dr Tayton-Martin brings broad experience of biotech company building, fund-raising, M&A, business development and operations with a strong track record of strategic partnership dealsHer more than 30 years of experience include leadership roles in the UK and US, from early research through to product approval in cancer immunotherapy, making her the ideal candidate to lead the next stage of execution of Evaxion's strategy Birgitte Rønø, who has served as interim Chief Executive Officer, will continue in her role as Chief Scientific OfficerSeasoned life science executive Jens Bitsch-Norhave will join as observer and advisor to the Board of Directors with the intention of seeking election at the

    10/27/25 8:00:00 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Evaxion Biotech Appoints Dr. Birgitte Rønø as Chief Scientific Officer

    Dr. Rønø has developed Evaxion's pre-clinical and early clinical oncology pipelineNewly-created Chief Scientific Officer role strengthens Evaxion's leadership team COPENHAGEN, Denmark, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ:EVAX) ("Evaxion" or the "Company"), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer, bacterial diseases and viral infections, announced today it has promoted its Senior Director, Immuno-Oncology, Birgitte Rønø, Ph.D, to the newly-created position of Chief Scientific Officer, effective immediately. Lars Wegner, CEO of Evaxion, said: "As Senior Di

    9/21/21 8:34:52 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Evaxion Biotech Appoints Lars Holtug to the Board of Directors

    COPENHAGEN, Denmark, May 26, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ:EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced today its shareholders elected Lars Holtug, a highly experienced financial professional with specific expertise in the healthcare industry, as a member of its Board of Directors. The vote was held at Evaxion's Annual General Meeting on May 25, 2021. Lars Holtug will also chair Evaxion's Audit Committee, taking over from Helen M. Boudreau, who chose not to stand for re-election for personal reasons. Marianne Søgaard, Chairwo

    5/26/21 8:30:00 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $EVAX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Evaxion Biotech A/S

    SC 13G - Evaxion Biotech A/S (0001828253) (Subject)

    11/14/24 3:29:53 PM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Evaxion Biotech A/S

    SC 13G/A - Evaxion Biotech A/S (0001828253) (Subject)

    11/6/24 4:09:57 PM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Evaxion Biotech A/S

    SC 13G - Evaxion Biotech A/S (0001828253) (Subject)

    1/23/24 3:29:11 PM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $EVAX
    Financials

    Live finance-specific insights

    View All

    Correction: Evaxion to announce business update and third quarter 2025 financial results on November 6, 2025

    Correcting press release issued under same heading: Date in body text corrected to "November 6, 2025" as in headline. COPENHAGEN, Denmark, October 31, 2025 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its third quarter 2025 financial results on Thursday November 6, 2025, before opening of the Nasdaq CM. Evaxion's Executive Management will host a conference call and webcast the same day at 14:30 CET/08:30 EST, presenting the update and results as well as taking questions. This event is free, open to the public and encouraged. To join the conference call, listen

    10/31/25 9:05:34 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Evaxion to announce business update and third quarter 2025 financial results on November 6, 2025

    COPENHAGEN, Denmark, October 31, 2025 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its third quarter 2025 financial results on Friday October 31, 2025, before opening of the Nasdaq CM. Evaxion's Executive Management will host a conference call and webcast the same day at 14:30 CET/08:30 EST, presenting the update and results as well as taking questions. This event is free, open to the public and encouraged. To join the conference call, listen to the presentation and ask verbal questions, please register in advance via this link to receive the dial-in telephone

    10/31/25 8:00:00 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation

    Equity Insider News Commentary Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Oct. 17, 2025 /PRNewswire/ -- Equity Insider News Commentary – MIT and Harvard scientists recently created engineered CAR-NK cells that hide from the immune system and more effectively destroy cancer, opening doors to off-the-shelf treatments doctors can administer immediately after diagnosis instead of waiting weeks for personalized cell production[1]. Eight new oncology approvals between July and September 2025 demonstrate how cellular immunotherapy platforms are solving manufacturing challenges while expanding from blood cancers into solid tumors, with researchers discovering ways to reprogram immune cell

    10/17/25 9:50:00 AM ET
    $EDAP
    $EVAX
    $GTBP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Biotechnology: Pharmaceutical Preparations